Advances in targeted therapy for relapsed or refractory acute myeloid leukemia in children
10.3760/cma.j.issn.1673-4408.2024.12.003
- VernacularTitle:儿童复发或难治性急性髓系白血病的靶向治疗进展
- Author:
Runji XIONG
1
;
Runming JIN
Author Information
1. 华中科技大学同济医学院附属协和医院儿科，武汉 430022
- Keywords:
Children;
Acute myeloid leukemia;
Relapse;
Refractory;
Targeted therapy
- From:
International Journal of Pediatrics
2024;51(12):803-808
- CountryChina
- Language:Chinese
-
Abstract:
In recent years，with the deepening understanding of the genetic characteristics and molecular markers of childhood acute myeloid leukemia（AML），researchers have identified potential pathogenic mechanisms related to relapsed or refractory（R/R）AML.This discovery has promoted the development and application of targeted therapeutic drugs for AML and is expected to improve the prognosis and therapeutic efficacy for children with R/R AML.This article reviews four classes of drugs that have made progress in the targeted therapy of R/R AML in children：gene-targeted therapies，signaling pathway targeting，targeting of cell surface antigens，and epigenetic inhibitors，with the aim of providing useful references and insights for clinicians and researchers.
